Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821896 | 0.90 | SMN1; SMN2 (0.43) | ADORA1LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6818702 | 0.90 | ADORA1 (0.46) | ADORA1 | |
| SCHEMBL6818732 | 0.90 | CYP1A2 (0.42) | ADORA1ALDH1A1HPGD | |
| SCHEMBL6822359 | 0.90 | HSD17B10 (0.43) | ADORA1HSD17B10 | |
| SCHEMBL6821443 | 0.89 | LMNA (0.43) | ADORA1LMNAHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL6822276 | 0.89 | ADORA1 (0.46) | ADORA1ALDH1A1HPGD | |
| SCHEMBL6821898 | 0.89 | ADORA1 (0.39) | ADORA1HSD17B10 | |
| SCHEMBL6822093 | 0.88 | SMN1; SMN2 (0.41) | ADORA1LMNASMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL6822553 | 0.88 | ADORA1 (0.38) | ADORA1LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6822509 | 0.88 | HPGD (0.43) | ADORA1LMNASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885LMNA 4472/4885SMN1; SMN2 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.